Nano-X Imaging Ltd (NNOX) Q4 2025 Earnings Call Transcript

Why It Matters

The launch validates Genio’s clinical differentiation and establishes a scalable revenue stream in the fast‑growing HGNS market, positioning Nyxoah for long‑term growth despite near‑term losses.

Key Takeaways

• FDA approved Genio in August 2025
• Q4 U.S. net revenue €3.5M
• Gross margin 64% in Q4
• Cash €48M, runway to 2027
• 2026 U.S. revenue to grow 25% sequentially

Pulse Analysis

The hypoglossal nerve stimulation (HGNS) market has emerged as a pivotal solution for obstructive sleep apnea, offering an alternative to continuous‑positive‑airway‑pressure therapy. Nyxoah’s Genio system distinguishes itself with bilateral stimulation, a single‑incision, battery‑free implant and full‑body MRI compatibility, attributes that have resonated with surgeons and patients alike. The August 2025 FDA approval not only cleared a regulatory hurdle but also positioned Genio to capture a share of the U.S. market, which accounts for the majority of global HGNS demand.

Following approval, Nyxoah executed a focused commercial rollout, deploying 25 sales representatives to target 125 of the top 400 high‑volume accounts and training 145 surgeons. This effort translated into €3.5 million of U.S. net revenue in Q4 and €5.6 million globally, while maintaining a robust 64% gross margin. Reimbursement clarity—Medicare covering 10% and commercial payers 90%—and the alignment of CMS’s interim C‑code with the CPT 64582 fee eliminated pricing uncertainty, accelerating adoption. Although operating losses rose to €83.5 million due to launch investments, the company’s €48 million cash position secures runway through 2027, underscoring financial resilience.

Looking ahead, Nyxoah projects a 25% sequential uplift in U.S. net revenue for 2026 as it expands its sales force to 40 reps covering 200 accounts. The upcoming Genio 2.2 patch promises a “step‑function” margin improvement, while the ACCESS study’s 12‑month data, slated for July 2026, will support a PMA supplement aimed at early‑2027 label expansion. These milestones suggest a transition from growth‑phase losses to sustainable profitability, offering investors a compelling narrative of clinical innovation translating into commercial traction in a high‑growth therapeutic niche.